President and CEO:
Bill Gruber joined Solace Therapeutics in August 2011 as President and CEO. Prior to this role, he co-founded Interlace Medical in August 2006 and served as their President and CEO until Interlace was acquired by Hologic in January 2011. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to Interlace, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing. In this role, he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent 10 years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter and Gamble. Bill received a BA degree from Washington State University.
Kevin G. Connors
Spray Venture Partners
Kevin Connors is founder of Solace and was the Company’s CEO until Bill Gruber joined in 2011. He is an accomplished entrepreneur and venture investor. Kevin has co-founded eight healthcare technology companies, and has had CEO roles in ten. These companies have focused on developing proprietary technology to address large unmet medical needs, such as emphysema, low back pain, cerebral aneurysms, uterine disorders and bladder dysfunction. Prior to founding Spray Venture Partners in 1996, Kevin was the founding CEO of Vesica Medical, a company focused on the surgical treatment of female urinary incontinence. Under his leadership, Vesica realized product sales within 18 months of formation and was acquired by Boston Scientific Corporation in 1995. Prior to Vesica, Kevin led medical device investment activity at DSV Partners in Newport Beach, California. Kevin earned his BSEE from the University of Notre Dame, his MSEE from the University of Dayton, and an MBA from Harvard Business School.
Founder and Managing Director:
Questa Capital Management
Prior to founding Questa Capital Management, Ryan Drant was a General Partner and venture capital investor with New Enterprise Associates (NEA) for close to 20 years. He specializes in healthcare investments in the medical device, healthcare services, health information technology and specialty pharma sectors. Present board memberships in addition to Solace include BENU, Carticept Medical, Cartiva, DSI Renal, ExploraMed, Intrinsic Therapeutics, Moximed, Neotract, PatientKeeper, Radiology Partners, Spine Wave and TriVascular. Ryan also serves on the board of the Medical Device Manufacturers Association (MDMA). Ryan is a three-time nominee to the Forbes Midas List of top venture capital investors. Prior to joining NEA, Ryan worked in the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco and the San Francisco office of Arthur Andersen & Co. Ryan received a BA degree from Stanford University.
New Enterprise Associates
Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University.
President and CEO: T2 Biosystems
John McDonough has served as President and Chief Executive Officer and a member of the board of directors at T2 Biosystems since November 2007. From 2003 to 2007, John held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, and ultimately served as President at Cytyc Development Corporation. John was responsible for designing and executing Cytyc Corporation’s growth strategy for expanding the company from a single product company with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He led the efforts that resulted in Cytyc’s acquisition by Hologic, Inc. in October 2007, for over $6 billion. John has served in senior executive management and CEO roles in several private and public companies. John received his B.S.B.A. from
Stacy Enxing Seng
Stacy Enxing Seng most recently served as an Executive in Residence for Covidien as well as the President of Covidien’s Vascular Therapies division. Stacy joined Covidien in July 2010 through the $2.6B ev3 acquisition where she was a founding member and executive officer responsible for leading ev3's Peripheral Vascular Division from inception. She has also held various positions at Boston Scientific Corporation, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. She is a Member of the Board of Directors
for Sonova Holding AG and a recent Director of Foundry & Innovation Research 1, Limited. Stacy received
a Master of Business Administration from Harvard University and has a BA in Public Policy from Michigan